Liraglutide In Overweight Patients With Type 1 Diabetes

Part of paid clinical trials in Buffalo, New York.

Sponsor
University at Buffalo
Study ID
NCT01753362
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to examine the effects of liraglutide (a drug used to treat type 2 diabetes) on glucose (sugar) control over the 26 week study period when used in addition to insulin.

Key Dates

Start date
Dec 31, 2012
Status verified
Dec 2019
Primary completion
Dec 31, 2017
Completion
Feb 28, 2018

Study Design

Enrollment
84 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: placebo
    subcutaneous daily injection
  • Active Comparator: liraglutide
    subcutaneous daily injection

Primary Outcome Measure

HbA1c [ Time Frame: 26 weeks ]

Locations (2)

FacilityCityStateZIPSite coordinators
diabetes endocrinology center of WNYBuffaloNew York14215-
Diabetes Endocrinology Research Center of WNYBuffaloNew York14215-

Find similar trials in Buffalo, NY

By condition
Type 1 diabetes
By specialty
Endocrinology
By research site
diabetes endocrinology center of WNY· Buffalo, NYDiabetes Endocrinology Research Center of WNY· Buffalo, NY

Related Studies